Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Recruiting now · Phase 1

Conditions studied: Metastatic Prostate Cancer

In brief

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Key facts

Study ID

NCT05413421

Run by

ORIC Pharmaceuticals

People needed

275

Starts

2022-06-01

Expected to finish

2028-04-01

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients with metastatic prostate cancer
• Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone
• Prior therapies:
• Part I (single agent ORIC-944 dose escalation): Any number of prior therapies are allowed, but must have progressed after at least one line of next generation ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) and must not have received more than 2 chemotherapy regimens in the mCRPC setting
• Part II (ARPI combination dose escalation): Must have received only 1 prior line of ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) in any setting; may have also received up to 1 prior line of chemotherapy in the mCSPC setting
• Part III (ARPI combination dose optimization): In addition to up to 1 prior line of chemotherapy in the mCSPC setting:
• Cohorts A and B: received only one 1 prior line of abiraterone in any setting
• Cohorts C and D: received only one 1 prior line of apalutamide, darolutamide, or enzalutamide in any setting:
• Evidence of progressive disease by PCWG3 criteria for study entry
• rising PSA, defined as a minimum of 2 rising values obtained a minimum of one week apart with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of progression), or
• confirmation of 2 new bone lesions on last systemic therapy, or
• soft tissue progression per RECIST 1.1
• Measurable and/or evaluable disease by RECIST 1.1
• Agreement and ability to undergo on-study punch skin biopsies and core tumor biopsies
• ECOG performance status of 0 or 1
• Adequate organ function

You may not qualify if…

• History or presence of CNS metastases, unless previously treated and stable
• History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
• Known, symptomatic human immunodeficiency virus (HIV) infection
• Active symptomatic Hepatitis B or C infection; patients with well controlled disease are eligible
• Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, short gut syndrome, etc) or other malabsorption syndromes that would reasonably impact drug absorption per investigator judgement
• Any other condition or circumstance (eg, clinical, psychological, familial, sociological, inability to swallow oral study drug) that, in the opinion of the investigator, may interfere with protocol compliance or contraindicates participation in the study

Where it is running

• Royal Marsden NHS Foundation Trust — Sutton, Surrey, United Kingdom (enrolling)
• South Florida Oncology and Hematology — Plantation, Florida, United States (enrolling)
• Illinois Cancer Specialists — Arlington Heights, Illinois, United States (enrolling)
• Comprehensive Urologic Care — Lake Barrington, Illinois, United States (enrolling)
• First Urology — Jeffersonville, Indiana, United States (enrolling)
• Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland — Baltimore, Maryland, United States (enrolling)
• Maryland Oncology Hematology — Silver Spring, Maryland, United States (enrolling)
• Karmanos — Detroit, Michigan, United States (enrolling)
• Minnesota Oncology Hematology — Minneapolis, Minnesota, United States (enrolling)
• Memorial Sloane Kettering Cancer Center — New York, New York, United States (enrolling)
• Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
• NEXT Oncology — Barcelona, Barcelona, Spain (enrolling)
• Vall d'Hebron Institute of Oncology — Barcelona, Barcelona, Spain (enrolling)
• NEXT Oncology — Madrid, Spain (enrolling)
• Rocky Mountain Cancer Center — Colorado Springs, Colorado, United States (enrolling)
• Keystone Urology Specialists — Lancaster, Pennsylvania, United States (enrolling)
• Amarillo Urology Research — Amarillo, Texas, United States (enrolling)
• Urology Clinics of North Texas — Dallas, Texas, United States (enrolling)
• Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States (enrolling)
• Virginia Oncology Associates — Fairfax, Virginia, United States (enrolling)
• University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
• Sydney Adventist Health — Wahroonga, New South Wales, Australia (enrolling)
• Bendigo Health — Bendigo, Victoria, Australia (enrolling)
• MidLantic Urology — Bala-Cynwyd, Pennsylvania, United States
• Peninsula Health — Frankston, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.